MAXCYTE, INC.

Regulatory Filings • Mar 1, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0875Y

MaxCyte, Inc.

01 March 2017

MaxCyte, Inc.

("MaxCyte" or the "Company")

Notice of Full Year Results

Maryland, USA - 1 March 2017: MaxCyte (LSE: MXCT), a US-based global company dedicated to accelerating the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines, will be announcing its full year audited results for the year ended 31 December 2016 on Monday 20 March 2017.

Doug Doerfler, Chief Executive Officer, will host a presentation and live conference call for analysts at 11.00am GMT on the day of the results at the offices of Consilium Strategic Communications, 41 Lothbury, London, EC2R 7HG.

For further information please contact:

MaxCyte	+1 301 944 1660
Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer
Nominated Adviser and Broker Panmure Gordon Freddy Crossley (Corporate Finance) Fabien Holler Duncan Monteith Tom Salvesen (Corporate Broking)	+44 (0) 20 7886 2500
Financial PR Adviser Consilium Strategic Communications	+44 (0)203 709 5700 [email protected]
Mary-Jane Elliott Chris Welsh Lindsey Neville

About MaxCyte

MaxCyte (LSE: MXCT), is a US-based global company dedicated to accelerating the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve development and commercialization challenges. This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides unparalleled consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade high-performance cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering platform is CE-marked and FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialize cell-based medicines.

MaxCyte is also developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture CAR therapies for a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.

For more information, visit http://www.maxcyte.com/

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORTPMJTMBJTBIR